Beat Müllhaupt

Beat Müllhaupt

Auto-generated profile, based on publicly available information

Beat Müllhaupt

Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Closed access
SBSarah Blach
Sarah Blach
SZStefan Zeuzem
Stefan Zeuzem
MMMichael Manns
Michael Manns
IAIbrahim Altraif
Ibrahim Altraif
ADAnn-Sofi Duberg
Ann-Sofi Duberg
HRHomie Razavi
Homie Razavi

1 June 2018 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Closed access
DRDevin Razavi-Shearer
Devin Razavi-Shearer
IGIvane Gamkrelidze
Ivane Gamkrelidze
MNMindie H Nguyen
Mindie H Nguyen
DCDing-Shinn Chen
Ding-Shinn Chen
PDPierre Van Damme
Pierre Van Damme
HRHomie Razavi
Homie Razavi

1 April 2010 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
ARAndri Rauch
Andri Rauch
ZKZoltán Kutalik
Zoltán Kutalik
PDPatrick Descombes
Patrick Descombes
TCTao Cai
Tao Cai
JIJulia Di Iulio
Julia Di Iulio
PBPierre–Yves Bochud
Pierre–Yves Bochud

5 December 2012 in Hepatology
Verified
Journal Article
Open access
PDF file
RBRafael Bañares
Rafael Bañares
FNFrederik Nevens
Frederik Nevens
FLFin Stolze Larsen
Fin Stolze Larsen
RJRajiv Jalan
Rajiv Jalan
AAAgustín Albillos
Agustín Albillos
OGon behalf of the RELIEF study group
on behalf of the RELIEF study group
Acute-on-chronic liver failure (ACLF) is a frequent cause of death in cirrhosis. Albumin dialysis with the molecular adsorbent recirculating system (MARS) decreases retained substances and improves hemodynamics and hepatic encephalopathy (HE). However, its survival impact is unknown. In all, 189 patients with ACLF were randomized either to MARS (n = 95) or to standard therapy (SMT) (n = 94). Ten patients (five per group) were excluded due to protocol violations. In addition, 23 patients (MARS: 19; SMT: 4) were excluded from per-protocol (PP) analysis (PP population n = 156). Up to 10 6–8-hour MARS sessions were scheduled. The main endpoint was 28-day ITT and PP survival. There were no significant differences at inclusion, although the proportion of patients with Model for Endstage Liver Disease (MELD) score over 20 points and with spontaneous bacterial peritonitis (SBP) as a precipitating event was almost significantly greater in the MARS group. The 28-day survival was similar in the two groups in the ITT and PP populations (60.7% versus 58.9%; 60% versus 59.2% respectively). After adjusting for confounders, a significant beneficial effect of MARS on survival was not observed (odds ratio [OR]: 0.87, 95% confidence interval [CI] 0.44–1.72). MELD score and HE at admission and the increase in serum bilirubin at day 4 were independent predictors of death. At day 4, a greater decrease in serum creatinine ( P = 0.02) and bilirubin ( P = 0.001) and a more frequent improvement in HE (from grade II-IV to grade 0-I; 62.5% versus 38.2%; P = 0.07) was observed in the MARS group. Severe adverse events were similar. Conclusion : At scheduled doses, a beneficial effect on survival of MARS therapy in patients with ACLF could not be demonstrated. However, MARS has an acceptable safety profile, has significant dialysis effect, and nonsignificantly improves severe HE. (Hepatology 2013)

1 January 2017
Verified
Book Chapter
Closed access
PKP Kern
P Kern
ASA Menezes Da Silva
A Menezes Da Silva
OAO Akhan
O Akhan
BMB Müllhaupt
B Müllhaupt
KVK A Vizcaychipi
K A Vizcaychipi
DVD A Vuitton
D A Vuitton

1 June 2016 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
MMMichael Manns
Michael Manns
DSDidier Samuel
Didier Samuel
EGEdward J Gane
Edward J Gane
DMDavid Mutimer
David Mutimer
GMGeoff McCaughan
Geoff McCaughan
XFXavier Forns
Xavier Forns